{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
The Chemours Co.
Chemours Co. Opens Weak with 5.45% Gap Down Amid Market Concerns
The Chemours Co. experienced a significant decline in its stock performance today, contrasting with the broader market's modest downturn. Despite a slight monthly gain, the company's financial metrics reveal a negative return on equity and a high price-to-earnings ratio, alongside a stable dividend yield and manageable debt levels.
Chemours Co. Experiences Revision in Its Stock Evaluation Amid Financial Challenges
The Chemours Co. has faced significant financial challenges, reporting a decline in net sales and operating profit for the quarter ending December 2025. Rising raw material costs and inefficiencies in inventory management have contributed to its struggles, prompting a need for strategic reassessment amid contrasting market performance.
Chemours Co. Hits Day High with 7.09% Surge Amid Market Decline
The Chemours Co. experienced a notable stock price increase on October 13, 2025, reaching an intraday high. However, the company has struggled over the past year, with a significant decline in stock value and net profit, alongside a high debt-to-equity ratio and an attractive dividend yield.
Chemours Co. Experiences Revision in Stock Evaluation Amid Mixed Market Signals
Chemours Co., a specialty chemicals company, has seen its stock price decline recently, trading at $15.80. The stock's performance has varied against the S&P 500, with mixed returns over different time frames. Technical indicators present a complex outlook, reflecting both bullish and bearish trends.
Is The Chemours Co. technically bullish or bearish?
As of October 3, 2025, Chemours shows a mildly bullish trend with mixed indicators, underperforming the S&P 500 significantly year-to-date and over the past year.
Is The Chemours Co. technically bullish or bearish?
As of October 3, 2025, The Chemours Co. shows a mildly bullish trend with mixed technical signals, having outperformed the S&P 500 recently but significantly underperformed year-to-date and yearly.
Is The Chemours Co. technically bullish or bearish?
As of October 3, 2025, The Chemours Co. shows a mildly bullish trend, supported by short-term bullish indicators, despite underperforming the S&P 500 over the past year.
Chemours Co. Experiences Revision in Stock Evaluation Amid Market Dynamics and Volatility
The Chemours Co. has experienced recent stock fluctuations, with a 52-week range between $9.13 and $22.38. Technical indicators present a mixed outlook, showing both bullish and bearish signals. Over the past year, Chemours' stock has underperformed compared to the S&P 500, which has seen positive gains.
Is The Chemours Co. technically bullish or bearish?
As of September 26, 2025, The Chemours Co. shows a bullish technical trend with strong daily indicators, despite underperforming the S&P 500 with a 1-year return of -24.71% compared to 15.64%.
Is The Chemours Co. technically bullish or bearish?
As of September 26, 2025, The Chemours Co. shows a bullish technical trend with strong daily indicators, but caution is advised due to its significant underperformance compared to the S&P 500.
Chemours Stock Forms Golden Cross, Signaling Potential Bullish Breakout
The Chemours Co. has recently experienced a Golden Cross, indicating a potential shift in momentum. Current technical indicators suggest a bullish outlook, despite a challenging year with an 8.98% decline. However, the stock has shown resilience, gaining 10.74% over the past month, outperforming the S&P 500.
Chemours Co. Experiences Revision in Stock Evaluation Amid Market Dynamics
The Chemours Co. has recently revised its evaluation amid market fluctuations, with its stock price at $17.01. The company has experienced significant volatility over the past year, with a 52-week high of $22.38 and a low of $9.13, while showing mixed technical indicators and varying performance compared to the S&P 500.
Is The Chemours Co. technically bullish or bearish?
As of September 9, 2025, The Chemours Co. shows a mildly bullish trend supported by positive MACD indicators, despite short-term bearish moving averages, with recent returns outperforming the S&P 500 over the past week and month but underperforming over the past year.
Is The Chemours Co. overvalued or undervalued?
As of August 5, 2025, The Chemours Co. is considered overvalued with a P/E ratio of 12 and a decline of 5.14% in stock performance over the past year, contrasting with the S&P 500's 17.14% gain, indicating a shift from a very attractive to a risky valuation grade.
Is The Chemours Co. overvalued or undervalued?
As of February 18, 2025, The Chemours Co. is considered undervalued with a P/E ratio of 12, a PEG ratio of 0.06, an EV to EBITDA of 7.55, a high dividend yield of 377.74%, and favorable comparisons to peers, despite a year-to-date stock performance lagging behind the S&P 500.
Is The Chemours Co. technically bullish or bearish?
As of June 9, 2025, The Chemours Co. exhibits a mildly bearish trend, with mixed signals from key indicators like MACD, Bollinger Bands, and moving averages suggesting weak bearish sentiment in the market.
Who are in the management team of The Chemours Co.?
As of March 2022, The Chemours Co. management team includes Independent Chairman Richard Brown, CEO Mark Vergnano, and Independent Directors Curtis Anastasio, Bradley Bell, Mary Cranston, Curtis Crawford, and Dawn Farrell, who oversee the company's strategic direction and governance.
What does The Chemours Co. do?
The Chemours Co. is a small-cap provider of performance chemicals in the specialty chemicals industry, with recent net sales of $1.368 billion and a market cap of approximately $1.906 billion. Key metrics include a P/E ratio of 12.00 and a dividend yield of 391.10%.
How big is The Chemours Co.?
As of Jun 18, The Chemours Co. has a market capitalization of $1.91 billion, with net sales of $5.80 billion and a net profit of $31 million for the latest four quarters. The balance sheet shows shareholder's funds of $604 million and total assets of $7.52 billion.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
